

# Puma Biotechnology

## Earnings Call

### Commercial Update



November 5, 2020

**nerlynx**<sup>®</sup>  
(neratinib) tablets




# Forward-Looking Safe Harbor Statement


*This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements, including, but not limited to, any adverse impact on Puma’s business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Puma’s Annual Report on Form 10-K for the year ended December 31, 2019, Puma’s Quarterly Report on Form 10-Q for the period ended March 31, 2020, and subsequent reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.*




# PUMA's Pharmacy and Distributor Network



# ~\$49.3 Million Net NERLYNX Revenue in Q3'2020




# ~3,600 Ex-factory Bottles were Sold in Q3'20










Includes Commercial SP and SD



# ~33% of Patients in Q3'20 Started at a Reduced Dose



# Rest of World Partnerships – Timelines

Region	Partner	Regulatory / Launch Milestones
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> <li>March 2019 – Approved in Australia</li> <li>December 2019 -- Approved in Singapore</li> <li>Q2/Q3 2020 - Approved in Brunei, Malaysia, New Zealand</li> </ul>
Israel	 MEDISON Creating Innovative Healthcare	<ul style="list-style-type: none"> <li>Q1 2020 – Launched</li> <li>Q3 2020- Approved in metastatic breast cancer</li> </ul>
Canada	 Knight	<ul style="list-style-type: none"> <li>July 2019 – Approved</li> <li>September 2020- metastatic sNDS accepted by HC</li> </ul>
Greater China	 CANbridge 北海康成	<ul style="list-style-type: none"> <li>November 2019 – Approved in Hong Kong</li> <li>April 2020 – Approved in China</li> <li>August 2020 – Approved in Taiwan</li> </ul>
Latin America	 PINT PHARMA	<ul style="list-style-type: none"> <li>Q1 2020 – Argentina-Launched</li> <li>Q2 2020 – Approved in Chile</li> <li>Q3 2020 – Approved in Ecuador</li> <li>2021 – Expected approvals in Brazil, Colombia, Mexico, Peru</li> </ul>
Europe Middle East North and West Africa South Africa Turkey	 Pierre Fabre	<p><b>Launch Timelines</b></p> <ul style="list-style-type: none"> <li>Q4 2019 – Germany-Launched</li> <li>Q4 2019 – United Kingdom-Launched</li> <li>Q4 2019 – Austria-Launched</li> <li>Q1 2020 – Sweden Launched</li> <li>Q1 2020 – Approved in Switzerland</li> <li>Q4 2020 – Planned launch in Finland</li> </ul>
South Korea	 BIXINK	<ul style="list-style-type: none"> <li>October 2020 – NDA Filed</li> </ul>

# Puma Biotechnology

## Earnings Call

### Commercial Update



November 5, 2020

**nerlynx**<sup>®</sup>  
(neratinib) tablets